Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Brainstorm Cell (BCLI)

Brainstorm Cell (BCLI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 128,206
  • Shares Outstanding, K 36,319
  • Annual Sales, $ 0 K
  • Annual Income, $ -31,810 K
  • 60-Month Beta -0.01
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.16
Trade BCLI with:

Options Overview

Details
  • Implied Volatility 119.58%
  • Historical Volatility 55.18%
  • IV Percentile 49%
  • IV Rank 10.78%
  • IV High 405.75% on 11/13/20
  • IV Low 84.98% on 08/05/21
  • Put/Call Vol Ratio 0.02
  • Today's Volume 618
  • Volume Avg (30-Day) 563
  • Put/Call OI Ratio 0.15
  • Today's Open Interest 18,586
  • Open Int (30-Day) 11,167

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.21
  • Number of Estimates 2
  • High Estimate -0.18
  • Low Estimate -0.24
  • Prior Year -0.14
  • Growth Rate Est. (year over year) -50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.11 +13.50%
on 09/14/21
3.80 -7.11%
on 09/15/21
+0.06 (+1.73%)
since 08/17/21
3-Month
3.11 +13.50%
on 09/14/21
4.21 -16.15%
on 08/06/21
-0.23 (-6.12%)
since 06/17/21
52-Week
2.92 +20.89%
on 05/11/21
17.95 -80.33%
on 10/09/20
-11.09 (-75.85%)
since 09/17/20

Most Recent Stories

More News
Innocan Pharma gained 350% in value this year Is it still a good time to buy? | BreezyScroll

Prospective investors should know that this is just the beginning, as according to financial analysts, InnoCan's stock surged due to the publication of its recent experimental trials. The exposure bolstered...

INNO.CN : 1.270 (-19.11%)
INNPF : 1.0300 (-18.94%)
TEVA : 8.99 (+0.45%)
PSTI : 3.00 (+1.35%)
BCLI : 3.53 (+1.44%)
InnoCan Pharma receives strong buy recommendation: Here is why

Those who invested in InnoCan Pharma's (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) a year ago are up 273%.

INNO.CN : 1.270 (-19.11%)
INNPF : 1.0300 (-18.94%)
TEVA : 8.99 (+0.45%)
PSTI : 3.00 (+1.35%)
BCLI : 3.53 (+1.44%)
BrainStorm Announces Second Quarter 2021 Financial Results and Provides a Corporate Update

/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial results for the first quarter ended...

BCLI : 3.53 (+1.44%)
BrainStorm Increases Commercial Manufacturing Capacity; Granted GMP Certification for a Second Production Site in Israel

/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that is has received Good Manufacturing Practice...

BCLI : 3.53 (+1.44%)
BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update

/PRNewswire/ --BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will hold a conference call to...

BCLI : 3.53 (+1.44%)
Brainstorm Announces Expansion of NurOwn® IP Portfolio with Grant and Allowance of Multiple Patents and Applications in Major Markets

/PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the grant and/or allowance of a series...

BCLI : 3.53 (+1.44%)
Global Gene and Cell Therapies Targeting CNS Disorders Market 2021-2026 Featuring Emerging Drugs - NurOwn (BrainStorm Cell Therapeutics) & Neuro-Cells (Neuroplast)

The "Gene and Cell Therapies Targeting CNS Disorders - Market Insights and Market Forecast - 2026" report has been added to ResearchAndMarkets.com's offering.

BCLI : 3.53 (+1.44%)
BrainStorm Announces Scientific Presentation of NurOwn® Exosome Preclinical ARDS Data at ISCT 2021 New Orleans VIRTUAL Meeting

, /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation today of a poster titled, "Molecular...

BCLI : 3.53 (+1.44%)
BrainStorm Announces First Quarter 2021 Financial Results and Provides a Corporate Update

, /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial results for the first quarter ended...

BCLI : 3.53 (+1.44%)
Brainstorm Cell Therapeutics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / April 26, 2021 / Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on April 26,...

BCLI : 3.53 (+1.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

BrainStorm Cell Therapeutics Inc. is a biotechnology company. It develops autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, Multiple Sclerosis and Parkinson's disease. Brainstorm Cell Therapeutics is based in New York.

See More

Key Turning Points

3rd Resistance Point 3.71
2nd Resistance Point 3.62
1st Resistance Point 3.58
Last Price 3.53
1st Support Level 3.45
2nd Support Level 3.36
3rd Support Level 3.32

See More

52-Week High 17.95
Fibonacci 61.8% 12.21
Fibonacci 50% 10.44
Fibonacci 38.2% 8.66
Last Price 3.53
52-Week Low 2.92

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar